Sight SciencesSGHT -0.76%72 Piotroski F-Score is 4 as of Jun. 25, 2026, which is at its 10-year median of 4.00. GuruFocus rates SGHT with a GF Score™ of 72/100 and a GF Value™ of $4.49 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Sight Sciences ranks worse than 56.27% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Sight Sciences has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Sight Sciences's Piotroski F-Score or its related term are showing as below:
SGHT'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 4 Max: 5
Current: 4
During the past 8 years, the highest Piotroski F-Score of Sight Sciences was 5. The lowest was 2. And the median was 4.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Sight Sciences Piotroski F-Score Related Terms
Sight Sciences Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Sight Sciences's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGHT vs QSI, TMCI, SI: Piotroski F-Score Comparison
For the Medical Devices subindustry, Sight Sciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sight Sciences Piotroski F-Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sight Sciences's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Sight Sciences's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Sight Sciences's current Net Income (TTM) was -37.25.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Sight Sciences's return on assets of this year was -0.28726095. Sight Sciences's return on assets of last year was -0.31753021.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Sight Sciences's gearing of this year was 0.3171313. Sight Sciences's gearing of last year was 0.2766253.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Sight Sciences's current ratio of this year was 5.86422948. Sight Sciences's current ratio of last year was 10.46906451.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Sight Sciences's number of shares in issue this year was 53.943. Sight Sciences's number of shares in issue last year was 51.291.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Sight Sciences's gross margin of this year was 0.86168969. Sight Sciences's gross margin of last year was 0.85658503.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Sight Sciences's asset turnover of this year was 0.6134562. Sight Sciences's asset turnover of last year was 0.50211494.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
1
+
0
+
0
+
0
+
1
+
1
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Sight Sciences has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Sight Sciences (SGHT) has a Piotroski F-Score of 4 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sight Sciences and its competitors. This is near median its historical median of 4.00. Over the past decade, Sight Sciences' Piotroski F-Score has ranged from 2.00 to 5.00. According to the industry distribution chart, Sight Sciences ranks #453 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 56.3%.
Is Sight Sciences' Piotroski F-Score too high?
Sight Sciences' current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 5.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Sight Sciences' value of 4 is 20% below this industry median. Based on the distribution chart, Sight Sciences ranks #453 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sight Sciences has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sight Sciences' Piotroski F-Score compare to QSI and TMCI?
According to the Medical Devices & Instruments industry distribution chart, Sight Sciences ranks #453 out of 805 companies for Piotroski F-Score. This places Sight Sciences in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Sight Sciences' value of 4 is 20% below this benchmark. Historically, Sight Sciences' own Piotroski F-Score has ranged from 2.00 to 5.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 5.00, Sight Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sight Sciences's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sight Sciences and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sight Sciences's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sight Sciences stock overvalued right now?
Based on GuruFocus' analysis, Sight Sciences (SGHT) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.49, compared to a current price of $5.46 — trading 21.6% above its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 20% below the Medical Devices & Instruments industry median of 5.00. Sight Sciences' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Sight Sciences (SGHT), the current Piotroski F-Score is 4 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sight Sciences (SGHT) Overvalued in 2026?
Based on GuruFocus' analysis, Sight Sciences stock appears to be overvalued.
The current stock price of $5.46 is trading 21.6% above its estimated GF Value™ of $4.49.
GuruFocus considers Sight Sciences to be Modestly Overvalued.
Key valuation signals for SGHT:
Piotroski F-Score: 4 (near median its 10-year median of 4.00)
GF Value™: $4.49 vs. price of $5.46 (21.6% above fair value)
Industry Position: 20% below the Medical Devices & Instruments median (#453 of 805)
No single metric tells the full story. See the SGHT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.
72GF Score
Get the complete analysis for SGHT
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGHT has been successfully added to your 
